COMP <GO>
MRVI vs ZYME // OPERATING MARGIN
Maravai LifeSciences Holdings Inc. (Class A) (NASDAQ) VS. Zymeworks Inc. (NASDAQ) • 15-METRIC TALLY: MRVI 1
— ZYME 6
■ METRIC PARITY
LAST: $7.19 (-7.94%) • MKT CAP: $2.03B
operating-margins
-60.00%
LAST: $28.99 (+1.33%) • MKT CAP: $2.02B
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRVI VS. ZYME)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MRVI | ZYME | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -32.20% | -2.80 | ZYME | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.22% | -1.71% | -1.51 | ZYME | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -28.30% | 38.90% | -67.20 | ZYME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.04 | 11.85 | -8.81 | ZYME | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | ZYME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.2 | 60.0 | -7.80 | ZYME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.03B | $2.02B | $11.8M | MRVI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MRVI REV | ZYME REV | MRVI GROSS % | ZYME GROSS % | MRVI FCF | ZYME FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $185.7M | $106.0M | 18.3% | — | -$70.7M | -$34.5M |
| FY 2024 | $259.2M | $76.3M | 41.8% | — | -$22.2M | -$112.0M |
| FY 2023 | $288.9M | $76.0M | — | — | $126.2M | -$118.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRVI // BETA —
ZYME // BETA —